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a  b  s  t  r  a  c  t
Aristolochic  acid  I  (AAI)  and  ochratoxin  A (OTA)  cause  chronic  kidney  diseases.  Recently,  the  contribution
of  hypoxic  injuries  and  angiogenic  disturbances  to  nephropathies  has been  suggested,  but  underlying
mechanisms  have  not  been  fully  clariﬁed  yet.
In  porcine  kidney  epithelial  cell  line,  LLC-PK1  cells,  treatment  with  non-toxic  doses  of  AAI  increased
whereas  with  OTA  decreased  production  of  vascular  endothelial  growth  factor  (VEGF),  the  angiogenic  fac-
tor with  well-deﬁned  functions  in  kidney.  Moreover,  the  activity  of  transcription  factors  regulating  VEGF
expression  was  differentially  affected  by examined  compounds.  Activity  of  hypoxia  inducible  factors
(HIFs)  and  SP-1  was  increased  by AAI  but  diminished  by OTA.  Interestingly,  AP-1  activity  was  inhibited
while  NFB  was  not  inﬂuenced  by both  toxins.  Mithramycin  A,  a  SP-1  inhibitor,  as  well  as  chetomin,
an  inhibitor  of  HIFs,  reversed  AAI-induced  up-regulation  of  VEGF  synthesis,  indicating  the importanceypoxia
LC-PK1
of  SP-1  and  HIFs  in  this  effect.  Additionally,  adenoviral  overexpression  of  HIF-2  but  not  HIF-1  pre-
vented  OTA-diminished  VEGF  production  suggesting  the  protective  effect  of  this  isoform  towards  the
consequences  exerted  by  OTA.
These observations  provide  new  insight  into  complex  impact  of AAI  and  OTA  on  angiogenic  gene reg-
ulation.  Additionally,  it adds  to  our  understanding  of  hypoxia  inﬂuence  on  nephropathies  pathology.. Introduction
Aristolochic acid (AA), a chemical found in Aristolochia and
sarum species, is present in a number of botanical products sold as
traditional medicines”, dietary supplements or weight-loss reme-
ies. AA is a ∼1:1 mixture of two forms, aristolochic acid I (AAI)
nd aristolochic acid II (AAII), of which the ﬁrst has higher nephro-
oxicity in cellular and animal models (Shibutani et al., 2007).
Abbreviations: AA, aristolochic acid; AAI, aristolochic acid I; AAII, aristolochic
cid II; AA-ATN, aristolochic acid-induced acute tubular necrosis; AAN, aristolochic
cid-induced nephropathy; AdGFP, adenoviral vectors containing GFP cDNA; AdHIF-
,-2,  adenoviral vectors containing HIF-1,-2 cDNA; -gal, -galactosidase; BEN,
alkan endemic nephropathy; CKDs, chronic kidney diseases; EMT, epithelial to
esenchymal cell transformation; GFP, green ﬂuorescent protein; HIF, hypoxia
nducible factor; HRE, hypoxia responsive element; HRP, horseradish peroxidase;
DH, lactate dehydrogenase; LLC-PK1, porcine kidney epithelial cell line; IARC, The
nternational Agency for Research on Cancer; OTA, ochratoxin A; ROS, reactive oxy-
en species; RT, room temperature; TGF, transforming growth factor ; VEGF,
ascular endothelial growth factor.
∗ Corresponding author. Tel.: +48 12 664 64 12; fax: +48 12 664 69 18.
E-mail address: agnieszka.loboda@uj.edu.pl (A. Loboda).
378-4274 © 2011 Elsevier Ireland Ltd. 
oi:10.1016/j.toxlet.2011.04.022
Open access under CC BY license.© 2011 Elsevier Ireland Ltd. 
AA is a rodent carcinogen and was responsible for aristolochic
acid-induced nephropathy (AAN) among women  under slimming
regime in Belgium and China (Arlt et al., 2002). Moreover, it is one
of the possible causative agents of Balkan endemic nephropathy
(BEN) (Stefanovic et al., 2006). The major targets of AA-induced
toxicity are kidneys and urothelial tracts (Stiborova et al., 2008).
AA was  reported to be among the most potent 2% of known car-
cinogens and herbal remedies contaminated with Aristolochia were
classiﬁed as carcinogenic to humans (Group 1) by the International
Agency for Research on Cancer (IARC) (Arlt et al., 2002; IARC, 2002).
BEN development is also closely correlated with the occurrence
of ochratoxin A (OTA), one of the mycotoxins produced by mem-
bers of Aspergillus and Penicillium family (O’Brien and Dietrich,
2005; Pfohl-Leszkowicz and Manderville, 2007). The presence of
this compound is proven for plant-derived products such as cereals,
coffee and bread. Still, it was also detected in cocoa, nuts, dried vine
fruits, grains as well as in wine. Pork and food products from pigs fed
with contaminated grain may  also be a source of OTA, what is linked
Open access under CC BY license.to the high stability of OTA and its long half-life in blood and tissues
(International Programme on Chemical Safety, 1990). The dose of
OTA may  vary in food from 0.5 mg/kg in baby foods to 10 mg/kg in
soluble coffee and dried vine fruits (Coronel et al., 2010) and the
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olerable intake was estimated by European Commission (1997)
t 5 ng/kg body weight/day. The data from OTA presence in plasma
ndicated the geographical differences, being the lowest in Japanese
eople and the highest in Argentina. The assessed level of OTA in
lasma in healthy people was 0.15 (min), 0.45 (mean) and 9.15
max) ng OTA/ml plasma (Coronel et al., 2010). Signiﬁcantly higher
lood serum or plasma levels of OTA in patients with kidney or
rinary disorders compared to healthy people have been reported,
ith an exceptionally high level of 1800 ng/ml found in one of the
erum Croatian samples (reviewed in Scott, 2005). OTA, similarly
o AA, is toxic mainly for kidney in domestic and laboratory ani-
als, and it was classiﬁed by IARC as a possible human carcinogen
group 2b) (IARC, 1993). Some data showed, however, a tendency
n the direction of group 2A toxicity (reviewed in Kuiper-Goodman,
996).
Recently, apart from well-established features of AAN and BEN
ncluding tubular proteinuria, the progressive ﬁbrosis, the epithe-
ial to mesenchymal cell transformation (EMT), proximal tubule
poptosis and kidney size reduction (Vukelic et al., 1992; Yang
t al., 2007), the changes in the kidney vasculature have been sug-
ested. In BEN the microvascular hyalinosis/sclerosis were found
Ferluga et al., 1991), whereas in AAN the impairment of vascular
etwork is connected with existence of severe hypoxia caused by
he reduction of peritubular capillary density (Sun et al., 2006a).
Hypoxia inducible factors (HIFs) are transcription factors sta-
ilized under hypoxic conditions, what leads to their nuclear
ranslocation and further to induction of various genes, like pro-
ngiogenic vascular endothelial growth factor (VEGF) (Zagorska
nd Dulak, 2004). VEGF plays a crucial role in kidney, where
t is produced mostly by glomerular epithelial cells (podocytes)
ut was also found in epithelial cells of the collecting and distal
ubules as well as in nephron’s proximal tubules (Baderca et al.,
006). It is responsible for the maintenance of the fenestrated
henotype of glomerular epithelial cells as well as it facilitates
he high rate of glomerular ultraﬁltration (Maharaj and D’Amore,
007). Moreover, the perturbances in its expression in tubular cells
as found in different kidney diseases, like in diabetic nephropa-
hy (Lindenmeyer et al., 2007) and progressive proteinuric renal
ailure (Rudnicki et al., 2009). In patients with chronic kidney dis-
ases (CKDs) (Futrakul et al., 2008) and with the chronic allograft
ephropathy (Hotchkiss et al., 2006) expression of VEGF is strongly
own-regulated. In addition to HIFs, multiple transcription factors,
ike SP-1, AP-1 or NFB, are known to regulate the expression of
EGF (Pages and Pouyssegur, 2005). SP-1, which is involved in
any cellular processes, such as cell cycle regulation, differenti-
tion and angiogenesis, is also connected with ﬁbrosis by affecting
ransforming growth factor- (TGF) pathway (Kum et al., 2007;
ysa et al., 2009). Therefore, SP-1 activity may  be important in the
A and OTA-induced toxicity.
Although there are evidences indicating that changes in vascu-
ature may  be one of the mechanisms observed in kidney diseases,
ystematic studies on the role of toxins in VEGF regulation as well
s the involvement of hypoxia/ischemia in the pathogenesis of
ifferent renal diseases are missing. Therefore, the objective of
he present study was to compare AAI and OTA impact on VEGF
xpression as well transcription factors regulating its expression in
ultured kidney tubulus cells. Comparison between effects of both
oxins on VEGF expression may  add to our understanding of the
ole of these toxins in nephropathy development.
. Materials and methods.1. Chemicals
Aristolochic acid I (AAI), ochratoxin A (OTA), mithramycin A, thiazolyl blue tetra-
olium bromide (MTT), dichloroﬂuorescein diacetate (DCFH-DA) and SYBR Green
ere obtained from Sigma–Aldrich. Oligo(dT) primers, dNTP’s, M-MLV  reverseetters 204 (2011) 118– 126 119
transcriptase, Non-radioactive Cytotoxic Lactate Dehydrogenase (LDH) assay and
Luciferase Activity Assay were obtained from Promega and chetomin was from
Alexis Biochemicals. The ELISA kit for human VEGF was procured from R&D Sys-
tems Europe. The cell proliferation BrdU ELISA kit was  bought from Roche, the Great
Escape SEAP Chemiluminescent Detection kit was from Clontech BD Biosciences and
SuperFect Transfection Reagent was procured from Qiagen. High glucose DMEM
medium was from Cytogen. Fetal bovine serum (FBS) and antibiotics (penicillin,
streptomycin) were from PAA. Rabbit polyclonal anti-HIF-1 (cat no. sc-10790) and
anti-HIF-2 (cat  no. sc-28706) antibodies were purchased from Santa Cruz Biotech-
nology, mouse monoclonal anti--tubulin (cat no. CP06) was from Calbiochem,
anti-rabbit IgG conjugated with horseradish peroxidase (HRP) (cat no. 7074) was
from Cell Signaling Technology whereas anti-mouse IgG conjugated with HRP (cat
no.  32230) was from Pierce. Goat anti-rabbit IgG conjugated with Alexa Fluor 568
(cat  no. A21069) was  from Invitrogen. Mounting medium with DAPI was bought
from Vector Laboratories.
2.2. Cell culture and incubation experiments
LLC-PK1 cell line, an established epithelial cell line derived from porcine renal
cortex, was  kindly supplied by Prof. Gerald Rimbach (Institute of Human Nutri-
tion and Food Science, Christian Albrechts University Kiel, Germany). The cells were
passed in high glucose DMEM medium, supplemented with 10% FBS, streptomycin
(100 U/ml) and penicillin (100 g/ml), and kept under standard conditions (37 ◦C, 5%
CO2). Toxins were prepared as a 50 mM stock solution (AAI in DMSO, and OTA in
methanol). In experiments with mithramycin A and chetomin, cells were pretreated
for  30 min  with mithramycin A or with chetomin, and then costimulated with AAI
for  next 24 h. For hypoxia experiments, cells were treated with OTA  and then put
into hypoxic conditions (0.5% O2, 5% CO2, 94% N2) for 24 h.
2.3. Cytotoxic tests
The effect of AAI (1–100 M) and OTA (2.5–100 M)  on porcine kidney cell
viability has been determined by non-radioactive cytotoxic LDH assay and MTT
conversion according to provider’s instruction.
2.4. Cell proliferation
LLC-PK1 cells were seeded at a density of 5,000 cells per well in a 96-well plate.
After 24 h non-conﬂuent cells were stimulated by OTA  and AAI and then cell
proliferation was assessed by bromodeoxyuridine incorporation by the use of BrdU
ELISA kit according to manufacturer’s instructions.
2.5. Transfection with reporter plasmids
LLC-PK1 cells growing to 70% conﬂuence in 24-well plates were transfected as
described previously (Loboda et al., 2005) with construct containing full VEGF pro-
moter or hypoxia responsive element (HRE) fragment of VEGF promoter (kindly
provided by Dr. Hideo Kimura, Chiba, Japan). The pAP-1-SEAP and pNFB-SEAP
vectors, containing the AP-1 and NFB binding regions, respectively, connected
to  secreted alkaline phosphatase (SEAP) reporter gene were purchased from Clon-
tech. The SP-1-luc plasmid, containing the upstream region of the VEGF promoter
from −135 to +3 bp, cloned into pAH1409 vector was kindly delivered by Dr Ulrike
Fiedler (Tumor Cell Biology, Freiburg, Germany). The pCMV-lacZ plasmid contain-
ing  the -galactosidase (-gal) gene driven by CMV  promoter was  from Promega
and was  co-transfected to cells together with one of the above described reporter
vectors. The activity of reporter gene, luciferase, -gal or SEAP was determined in
cell  lysates or cell culture media, respectively. Determination of luciferase enzyme
activity was done according to manufacturer’s protocol using Tecan plate reader.
Chemiluminescent SEAP assay was performed according to the vendor’s protocol
with a modiﬁcation, as described previously (Boesch-Saadatmandi et al., 2008).
2.6. Transduction of the cells with adenoviral vectors
Adenoviral vectors containing HIF-1 or HIF-2 cDNA (AdHIF-1, AdHIF-2)
were a kind gift from Prof. Seppo Yla-Herttuala (Kuopio, Finland) and Prof. Lorenz
Poellinger (Stockholm, Sweden). The pAdHIF-1 was generated as described pre-
viously (Pajusola et al., 2005). Brieﬂy, construct was stabilized against prolyl
hydroxylation and subsequent ubiquitin-mediated proteolytic degradation in nor-
moxic conditions by point mutations (P402A/P563A). A control vector (AdGFP) was
produced using the Adeno-X system as described previously (Loboda et al., 2009).
2.7. Reverse transcription–polymerase chain reaction and real-time PCR
RNA isolation and RT-PCR were performed as described previously (Loboda et al.,
2005).  Quantitative RT-PCR was performed using StepOnePlusTM Real-Time PCR Sys-
tems (Applied Biosystems). The real-time PCR reaction mixture, equalized with ultra
pure water to 15 l, contained 7.5 l of SYBR Green, 0.75 l of both reverse and for-
ward primer, and 50 ng of cDNA. Speciﬁc primers for VEGF (5′ CTG GTC TTG GGT
GCA  TTG 3′; 5′ CAC CGC CTC GGC TTG TCA CAT 3′), HIF-1 (5′ TGC TTG GTG CTG ATT
TGT GA 3′; 5′ GGT CAG ATG ATC AGA GTC CA 3′), HIF-2 (5′ TCC GAG CAG TGG AGT
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Fig. 1. AAI and OTA affect LLC-PK1 cell viability and proliferation. Cells were cultured in the presence of increasing concentrations of AAI and OTA for 24 h. Cell viability,
a TA (B
c f cell p
o
C
C
G
u
2
t
2
s
w
R
m
w
5
w
5
m
o
t
t
2
p
H

w
m
C
2
D
t
w
tssessed  by measurement of LDH release showed that 10 M AAI (A) and 25 M O
oncentration of both toxins analysis of BrdU incorporation pointed out inhibition o
f  at least 3 experiments performed in duplicates; *p < 0.05 vs control
AT TCA G 3′; 5′ GTC CAA ATG TGC CGT GTG AAA G 3′), SP-1 (5′ AAG AAG GGA GGC
CA GGT GTA G 3′; 5′ CAT GAC GTT GAT GCC ACT GTT G 3′) and constitutive EF2 (5′
CG GTC AGC ACA ATG GCA TA 3′; 5′ GAC ATC ACC AAG GGT GTG CAG 3′) have been
sed.
.8.  ELISA assays
Cell culture media were collected and concentration of VEGF protein was  quan-
iﬁed following the manufacturer’s protocol.
.9. Immunocytochemistry
Cells were seeded on eight-chamber culture slides (BD-Falcon). After 24 h of
timulation with AAI and OTA, cells were ﬁxed (20 min, 4% formaldehyde, RT),
ashed three times with PBS and permeabilized (20 min, 0.1% Triton X100 in PBS,
T).  After washing three times with PBS and blocking (1 h, 3% BSA in PBS, RT), pri-
ary rabbit IgG antibodies: anti-HIF-1 and anti-HIF-2 antibodies, respectively,
ere added (overnight, 1:300 in 3% BSA in PBS, 4 ◦C). After washing three times for
 min  with PBS, incubation with the secondary anti-rabbit IgG antibody conjugated
ith AlexaFluor (30 min, 1:1000 in 3% BSA in PBS, RT) and washing three times for
 min  with PBS, mounting medium with DAPI was  used. The observation of speci-
ens was  done by the use of ﬂuorescent microscope with green and UVA ﬁlter in
rder to detect red ﬂuorescence and blue signal from AlexaFluor and DAPI, respec-
ively. In negative control chambers the primary antibodies were omitted in order
o  verify the level of autoﬂuorescence and unspeciﬁc binding.
.10. Western blotting
Total cellular protein was isolated from LLC-PK1 cells and western blotting was
erformed as described previously (Loboda et al., 2005). Rabbit polyclonal anti-
IF2 (Santa Cruz Biotechnology, cat no. sc-28706) and mouse monoclonal anti-
-tubulin (Calbiochem, cat no. CP06) antibodies were used followed by incubation
ith the secondary antibodies (anti-rabbit HRP–Cell Signaling, cat no. 7074 and anti-
ouse HRP–BD Biosciences cat no. 554002, respectively) and Super Signal WestPico
hemiluminescence Substrate.
.11. Determination of intracellular reactive oxygen species generation using
CFH-DA oxidationThe assay was  performed by the use of DCFH-DA (10 M)  which was  added for
he  last hour of incubation. The ﬂuorescence (excitation 485 nm,  emission 535 nm)
as  measured from cell lysates. Obtained data were normalized to protein concen-
ration values. As a positive control for test 4 h stimulation with PGJ2 was used.) are the highest non-toxic concentrations. After 24 h stimulation with non-toxic
roliferation after delivery of 5 and 10 M AAI as well as after 25 M OTA (C). Mean
2.12. Statistical analysis
All experiments were performed in duplicates and were repeated at least three
times unless otherwise indicated. Data are presented as mean ± SD. Statistical eval-
uation was  done by analysis of variance (ANOVA), followed by a Bonferoni post hoc
test for multiple comparisons, or with Student’s t-test for two group comparisons.
Differences were accepted as statistically signiﬁcant at p < 0.05.
3. Results
3.1. AAI and OTA attenuate LLC-PK1 proliferation
Firstly, we  determined the effect of AAI (1–100 M)  and OTA
(2.5–100 M)  on the viability of porcine kidney LLC-PK1 cells. Using
the LDH release assay we found that the highest non-cytotoxic con-
centration of AAI was  10 M and of OTA was  25 M (Fig. 1A and
B). As the results of MTT  test (data not shown) were in accordance
to LDH assay such doses were chosen as the maximal ones for all
further experiments.
Then we  measured cells proliferation and we  showed that AAI
as well as OTA at non-toxic doses inhibited BrdU incorporation and
caused attenuation of LLC-PK1 proliferation (Fig. 1C).
3.2. AAI and OTA differentially regulate VEGF production
We  investigated the effect of both toxins on expression of VEGF,
main pro-angiogenic factor with well-deﬁned functions in kidney
(Maharaj and D’Amore, 2007). VEGF transcription was activated by
AAI as determined by luciferase assay in cells transfected with a
reporter plasmid containing a human full-length VEGF promoter
(Fig. 2A) as well as evidenced by increased VEGF mRNA expres-
sion (Fig. 2B). In contrast, the effect of OTA on VEGF transcription
was  inhibitory, both on the VEGF promoter activity (Fig. 2A) and
mRNA level (Fig. 2B). Basal VEGF protein production in LLC-PK1
cells ranges around 200–300 pg/ml and it was inﬂuenced by both
toxins comparable to mRNA level. ELISA test demonstrated that AAI
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Fig. 2. AAI elevates whereas OTA diminishes VEGF production in LLC-PK1 cells. LLC-PK1 cells were transfected with reporter plasmid containing luciferase encoding
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elivery was  observed (A). Analysis of mRNA level by real-time PCR (B) and prot
xpression after AAI and OTA adding, respectively. Mean of 3 experiments perform
lightly but signiﬁcantly elevated, whereas OTA strongly decreased
EGF protein level (Fig. 2C).
.3. AAI and OTA inﬂuence activity of transcription factors
In order to investigate the potential mechanisms of alterations
n VEGF production we  checked the effect of AAI and OTA on the
ctivity of transcription factors known to regulate VEGF expression
the binding sites of which are located within VEGF promoter), such
s HIFs, SP-1, AP-1 and NFB (Pages and Pouyssegur, 2005).
Using the cells transfected with a reporter construct regulated
y the hypoxia responsive element (HRE) from the VEGF promoter
e demonstrated that AAI activated whereas OTA diminished HRE
ctivity (Fig. 3A) at concentrations tested. Moreover, we showed
hat AAI and OTA exerted opposite effect on SP-1 activity (Fig. 3B).
AI was found to produce increase in SP-1 activity (Fig. 3B) but
t did not affect SP-1 mRNA level (Fig. S1A). In contrast, OTA
educed activity of SP-1 (Fig. 3B) and SP-1 mRNA level was concomi-
antly inhibited by ∼42 ± 18%. Additionally, AP1-SEAP construct
as employed to determine the effect of toxins on AP-1 activity. As
bserved previously (Boesch-Saadatmandi et al., 2008) and con-
rmed in this study, OTA diminished AP-1 activity. AAI delivery
xerted also inhibitory effect (Fig. 3C), although not so strong as
TA. In our hands, the activity of NFB transcription factor was not
nﬂuenced by non-toxic doses of AAI and OTA (Fig. S1B).
In order to verify the effect of both toxins on HIFs transcription
actors activity we have performed the immunoﬂuorescent staining
s well as western blot for speciﬁc HIF isoforms. Stimulation with
AI elevated nuclear accumulation of HIF-1 and HIF-2  isoforms
Fig. 3D, E, middle column) whereas after OTA delivery inhibition
as observed (Fig. 3D, E right column). Also western blot analysis
f HIF-2 protein revealed inhibition after OTA and up-regulation
aused by AAI stimulation (Fig. 3F). As ROS are known to affectelevation of VEGF promoter activity 24 h after AAI and diminishment after OTA
oduction by ELISA (C) indicated the enhancement and down-regulation of VEGF
uplicates; *p < 0.05 vs control.
HIF level (reviewed in Stachurska et al., 2010) in order to verify
the possible mechanism of alterations in HIF level we investigated
the effect of AAI and OTA on ROS generation. We observed previ-
ously (Boesch-Saadatmandi et al., 2008) as well as in this study, the
enhancement of ROS generation after OTA delivery, however AAI
did not affect ROS level (Fig. 3G). Therefore, increase in HIFs evoked
by AAI is not caused by ROS.
3.4. AAI increases VEGF expression via SP-1 and HIF transcription
factors
As AAI concomitantly elevates VEGF expression and activity of
SP-1 and HIFs, we  investigated the possible role of SP-1 and HIFs
transcription factors in induction of VEGF production evoked by
AAI. Mithramycin A was used to silence SP-1 activity (Blume et al.,
1991) whereas HIFs were inhibited with chetomin (Kung et al.,
2004). We  found out that AAI-induced VEGF transcription, both
promoter activity (Fig. 4A) and mRNA level (Fig. 4B) were attenu-
ated by 1 M mithramycin A. Similar effect was also observed on
VEGF protein level (Fig. 4C). In addition, 60 nM chetomin atten-
uated AAI-induced VEGF protein production measured by ELISA
(Fig. 4D) suggesting also the role for HIFs in observed effect. How-
ever, AAI did not affect hypoxia-enhanced HRE activity (Fig. S2A)
and hypoxia-induced VEGF production (Fig. S2B).
3.5. Hypoxia and HIF-2  ˛ but not HIF-1  ˛ attenuate the effect of
OTA on VEGF production
In order to investigate the possible involvement of HIFs in the
observed down-regulation of VEGF by OTA in LLC-PK1 cells, ﬁrstly
we  veriﬁed the effect of OTA stimulation in hypoxic conditions.
Basal level of VEGF was induced after 24 h of culturing of cells
in 0.5% O2 and decrease of VEGF production caused by OTA was
122 A. Stachurska et al. / Toxicology Letters 204 (2011) 118– 126
Fig. 3. AAI and OTA differentially regulate the activity of HRE and SP-1 but both attenuate AP-1 activity. 24 h after transfection with HRE-luc (A), SP-1-luc (B) and AP-1-SEAP
(C)  reporter plasmids LLC-PK1 cells were stimulated with AAI and OTA for next 24 h. Analysis demonstrated AAI-elevated and OTA-diminished HRE activity (A). SP-1 activity
was  enhanced after AAI and down-regulated after OTA (B) adding. Both AAI and OTA diminished AP-1 activity (C). Immunocytochemical staining showed that the stabilization
o fter O
b  not af
d ern bl
r
O
h
h
i
o
H
o
o
V
p
e
4
t
t
p
f
t
2f  HIF-1 (D) and HIF-2 (E) was  elevated after AAI (middle column) but decreased a
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uplicates, D, E-representative immunoﬂuorescent staining, F–representative west
eversed by hypoxia (Fig. 5A, B). We  also investigated the effect of
TA and hypoxia on HRE activity and we found that OTA diminished
ypoxia-enhanced HRE activity (data not shown).
As both HIF-1 and HIF-2 transcription factors may  mediate the
ypoxic response, we investigated which HIF isoform is involved
n the decrease of VEGF by OTA. For this purpose we used aden-
viral vectors harboring encoding sequences of stable HIF-1  or
IF-2, which allowed for signiﬁcant increase in the expression
f both isoforms with any mortality (data not shown). Adenoviral
verexpression of HIF-2  but not HIF-1 caused increase of basal
EGF level as well was able to reverse the diminishment of VEGF
roduction by OTA, suggesting that HIF-2 is crucial for the observed
ffects in kidney tubular cells (Fig. 5C, D).
. Discussion
The carcinogenic effects of aristolochic acid (AA) and ochra-
oxin A (OTA) are widely described. Despite many trials aiming
o discover the mechanism of their involvement to nephropathy
rogression, the sequence of events is still not clear.
The two main components of AA, AAI and AAII are responsible
or nephropathy progression, however AAI is more potent cyto-
oxic agent towards kidney epithelium (Arlt et al., 2002; Liu et al.,
009). Nephrotoxic activity of OTA is well-documented, however,TA (right column) delivery. HIF-2 expression was increased by AAI and diminished
ter AAI stimulation (G). Mean of 3 (A, B, G) and 2–3 (C) experiments performed in
ot; *p < 0.05 vs control.
species-dependent discrepancies between man, pig and rodents
are underlined. Such variations may  be caused by the differences
in the binding of OTA to serum proteins, oral bioavailability, the
half-life of OTA in serum as well as in the different plasma clear-
ance between species (reviewed in Petzinger and Ziegler, 2000).
In the present study, porcine renal proximal tubule epithelial cells
(LLC-PK1), a well characterized cell line often used in toxicological
studies (Dietrich et al., 2001) was  chosen as a model for investiga-
tion. Importantly, the high susceptibility of pigs towards OTA and
their importance for livestock production is well-known and pork
as well as food products from pigs fed with contaminated grain
may  also be a source of OTA (International Programme on Chemical
Safety, 1990). Moreover, it is well established that proximal tubu-
lar cells are the main site of toxicity of both OTA and AAI. Proximal
tubule injury is observed in aristolochic acid nephropathy in rats
(Mengs, 1987; Lebeau et al., 2005) and analysis of both kidney
functions and renal biopsies from AAN patients showed increased
tubular proteinuria, impairment of proximal tubule functions and
tubular necrosis (Depierreux et al., 1994). OTA was shown to be
removed by tubular, but not glomerular ﬁltration to the urine and
in vivo studies underlined that OTA affects the proximal part of the
nephron (Groves et al., 1998).
In AAN (Depierreux et al., 1994; Yang et al., 2005) and other
kidney diseases (Neusser et al., 2010) tubulointerstitial damage
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Fig. 4. Induction of VEGF by AAI goes through SP-1 and HIFs activation. LLC-PK1 cells were transfected with reporter plasmid containing luciferase encoding sequence under
the  control of VEGF promoter. 24 h after transfection cells were prestimulated with 1 M mithramycin A (A–C) or 60 nM chetomin (D) for 30 min  and then AAI was  added for
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A4  h. The elevation of VEGF promoter activity (A), mRNA level (B) as well as VEGF pr
.  Moreover, inhibition of HIF activity by chetomin caused the reversal effect on AA
uplicates; *p < 0.05 vs control; #p < 0.05 vs AAI-treated cells.
bserved during kidney ﬁbrosis may  be the effect of blood ves-
el injury. In the proper vessel functioning an important role plays
ascular endothelial growth factor (VEGF), which in kidneys is
xpressed both in podocytes and additionally in proximal tubular
ells (Baderca et al., 2006), which are the main site of AAI as well as
TA injury. Moreover, both tubular and glomerular VEGF may play
n important role in the maintenance of peritubular or glomeru-
ar capillaries. Diminished VEGF production may  lead to decreased
ndothelial survival and angiogenesis as well as tubular damage by
ig. 5. Hypoxia and HIF-2 attenuate the diminishment of VEGF production evoked by 
nd  stimulated by 25 M OTA. OTA attenuated induction of VEGF expression evoked by 
evel  assessed by ELISA (B). Overexpression of HIF-2 but not HIF-1 abolished the dim
ean  from 2 (A), 3 (B), 3–5 (C) or 3–4 (D) experiments performed in duplicates, *p < 0.0
dGFP + OTA (C, D). level (C) evoked by AAI was  reversed by inhibition of SP-1 activity by mithramycin
uced VEGF protein level (D). Mean of 3 (A, B, C) or 2 (D) experiments performed in
ischemia (reviewed in: Schrijvers et al., 2004). The importance of
the alterations in VEGF expression in epithelial cells of proximal and
distal tubules was  shown in human diabetic nephropathy patients
(Lindenmeyer et al., 2007) as well as in patients with progressive
proteinuric renal failure (Rudnicki et al., 2009).We investigated the effect of AAI and OTA on VEGF, the potent
pro-angiogenic factor, which is claimed to affect the nephropathy
progression. The data concerning the role of VEGF in development
of AAN are still not clear, although it seems that regulation of VEGF
OTA. LLC-PK1 cells were cultured under normoxic and hypoxic conditions for 24 h
hypoxia on mRNA level determined by real-time PCR (A) as well as on the protein
inishment of VEGF expression evoked by OTA on mRNA (C) and protein (D) level.
5 vs. control (A, B); vs. relevant AdGFP control (C, D), #p < 0.05 vs. OTA (A, B); vs.
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xpression plays an important role in this disease. VEGF expression
as reported to be down-regulated in rats with chronic AAN (Sun
t al., 2006b)  as well as in acute AAN rat model (Wen  et al., 2008).
n contrast, it was shown that in AA-induced acute tubular necrosis
AA-ATN) VEGF expression is elevated in renal tubules compared
o control group, nevertheless, the expression was lower than in
ntibiotic-induced ATN (Yang et al., 2007). In our study we  observed
he elevation of VEGF transcription as well as protein expression
fter AAI treatment in LLC-PK1 cells. Interestingly, we showed that
TA has different effect on VEGF production compared to AAI in
hort-term treatment as potent inhibition of VEGF expression in
LC-PK1 cells was observed after OTA stimulation. In male F344/N
ats treated with OTA no alterations in urinary level of VEGF was
ound (Hoffmann et al., 2010), however, the level of VEGF in urine
ay  differ from ones present in organs or in serum. As VEGF may  be
roduced by podocytes as well as epithelial tubular cells in order to
etter understand the effects evoked by AAI/OTA it is important to
etermine the production of VEGF by both types of cells in in vivo
tudies.
In order to investigate the mechanism of differential effect of
AI and OTA on VEGF production we veriﬁed the effect of both tox-
ns on the activity of transcription factors, which binding sites are
resent in VEGF promoter, such as HIFs, AP-1, NFB or SP-1 (Pages
nd Pouyssegur, 2005). Our data indicate that both toxins exert
omplex effect on various transcription factors, and as the result
hey may  differentially regulate VEGF expression. AAI treatment
aused SP-1 and HIFs up-regulation, whereas AP-1 was  inhibited
fter 24 h of toxin delivery. Similarly, OTA treatment diminished
P-1 activity, but it also potently down-regulated SP-1 and HIFs
ctivity. Moreover, the activity of NFB was inﬂuenced neither by
AI nor by OTA. Such complicated data show that, although both
oxins induced kidney damage, the mechanisms are different and
hould be carefully investigated in details. Additionally, the effect
ay  be cell-type dependent as in human HKC-8 cells only the effect
f OTA on HRE and AP-1 activity was the same as in LLC-PK1 cells,
hereas NFKB was induced and SP-1 activity was not affected by
his toxin (Fig. S3).  In pheochromocytoma PC-12 cells the inhibition
f AP-1 (Oh et al., 2004), whereas in 12-day rat embryo midbrain
ells the activation of this factor by OTA was observed (Hong et al.,
002). In contrast to our data, where we did not observe the alter-
tions in NFB  activity after OTA delivery, such activation was
hown in proximal OK cells (Sauvant et al., 2005), in immortal-
zed human kidney epithelial cells (IHKE) (Rached et al., 2006) as
ell as in 12-day rat embryo midbrain cells (Hong et al., 2002).
n the other hand, in LPS-activated RAW264.7 macrophages DNA
inding activity of NFB was considerably lower after AAI treat-
ent in comparison to control cells (Liu et al., 2011). However,
uch differences may  be caused by the dose and time of stimula-
ion in individual experiment. In case of SP-1, there are no data
oncerning the effect of OTA on activity of this transcription factor,
o we have shown for the ﬁrst time the diminishment of SP-1 activ-
ty after OTA. Moreover, our results indicating inhibitory effect of
TA on HRE activity and HIFs transcription factors are also unique.
o our best knowledge, only one paper showing increased mRNA
evel for HIF-1  in rat proximal tubule cells after OTA treatment
as published already but the protein level was not investigated
Luhe et al., 2003). However, in case of HIF proteins, the protein
tability is much more crucial, therefore these data and our data do
ot exclude each other.
The knowledge about AA inﬂuence on the activity on transcrip-
ion factors is also very limited. We  have presented for the ﬁrst
ime that AAI exerts opposite effect than OTA on SP-1 and AP-1,
nhancing and diminishing their activity, respectively. The already
ublished data about the effect of AA on NFB  is contradictory, as
nhibition in human HK-2 cells (Chen et al., 2010) and induction in
idney of Hupki (human TP53 knock-in) mice (Arlt et al., 2011) hasetters 204 (2011) 118– 126
been observed. Interestingly, in our hands activity of NFB  was not
affected but we observed HIF induction after AAI delivery. These
data are in accordance with results from animal studies. The pres-
ence of hypoxia was  also observed in male Wistar rats treated with
AAI for 4 days (Cao et al., 2010). In rat model AA evoked elevated
nuclear staining for HIF-1  with concomitant reduction in VEGF
production in long (8–16 weeks) (Sun et al., 2006a,b) and short
(4–7 days) term (Wen  et al., 2008) experiments. Moreover, this
increase of nuclear HIF-1  was  present in the tubular cells in dam-
aged area (Wen  et al., 2008). However, in our studies concomitantly
with HIF stabilization we observed elevation of VEGF production.
The discrepancies between our results and published data may
come from different time of stimulation and species-dependent
differences in response. Additionally, it is possible that in case of
longer AA treatment other transcription factors known to regulate
VEGF expression, like AP-1, may  play a role. Therefore, it seems that
regulation of VEGF expression after delivery of AAI is much more
complex. Thus, the understanding of the sequence of events evoked
by AA is important to identify the origin of AAN development and
still needs to be clariﬁed.
The most important part of our study is the discovering of the
possible mechanism of AAI/OTA action on VEGF production. The
augmentation of HIFs and SP-1 transcription factors activity by AAI
was  paralleled with the up-regulation of VEGF transcription and
protein level. By the use of mithramycin A, an inhibitor of SP-1
activity, and chetomin, an inhibitor of HIFs, we showed that AAI-
elevated VEGF production is reversed after inhibition of SP-1 and
HIFs, what conﬁrms the role of these transcription factors in the
effect of AAI on VEGF expression.
The next salient ﬁnding of our study is that hypoxia attenuated
the inhibitory effect of OTA on VEGF production. In the kidney
the localization of HIF isoforms depends on cell type with HIF-
1 presence in the tubular epithelia, whereas HIF-2 expression
mostly in endothelial, glomerular and interstitial cells (Rosenberger
et al., 2005). Although different role of HIF isoforms in kidney
development may  be the result of divergent localization in cells,
it is well documented that HIF-1 and HIF-2 also differs in regu-
lation of gene expression (reviewed in Loboda et al., 2010). HIF
stabilization elevates angiogenesis and therefore it may attenuate
adverse effects of toxins delivery. On the other hand, HIF trig-
gers also the expression of connective tissue growth factor (CTGF),
which exhibit proﬁbrotic effects (Higgins et al., 2004). Thus, long-
term activation of HIF may  lead to ﬁbrosis development. Therefore
the proper balance in HIF activation is crucial for therapeutic
effect.
Our data indicate that in prevention of diminishment of VEGF
production evoked by OTA in kidney proximal tubular epithelial
cells HIF-2 but not HIF-1  plays a crucial role. Additionally, we
found that HIF-1  overexpression diminished VEGF production,
whereas only AdHIF-2 transduction resulted in elevation of VEGF
expression. Therefore, it seems that two  isoforms of HIF may play a
distinct role in regulation of VEGF production in porcine proximal
tubular epithelial cells, which are the major target of OTA action.
Moreover, only HIF-2 exerts protective effect, especially against
short-term acute kidney injuries. These results are in accordance
with studies showing that HIF may  be protective in acute renal
injuries whether in case of chronic ones they exert opposite effect
(Manotham et al., 2004). Still, the role of each HIF isoform in differ-
ent kidney cell types may  be various. Additionally, also the other
factors, such as AP-1 and SP-1, should be investigated in this con-
text.
In conclusion, we  have shown complicated pattern of VEGF
regulation by different toxins affecting kidney biology. To our
knowledge, the inﬂuence of AAI and OTA on some transcription fac-
tors have not been investigated before and further investigations
are necessary to analyze this intriguing effects.
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